Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing a drug called Carfilzomib in different doses. The drug is given with other medicines called Cyclophosphamide, Dexamethasone, and Granulocyte colony-stimulating factor (G-CSF). Different groups of people are given increasing amounts of the drug to see if it is safe and effective.
This study is testing a drug called Carfilzomib in different doses. The drug is given with other medicines called Cyclophosphamide, Dexamethasone, and Granulocyte colony-stimulating factor (G-CSF). Different groups of people are given increasing amounts of the drug to see if it is safe and effective.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: